research Abiraterone and spironolactone in prostate cancer: a combination to avoid
Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
Search
for
Sort by
Research
30 / 1000+ results 
research Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
research Revising the role of the androgen receptor in breast cancer
The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
research Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
Certain drugs that block specific enzymes can help treat prostate diseases.
research Are sex discordant outcomes in COVID-19 related to sex hormones?
Sex hormones may affect COVID-19 severity, with men often faring worse, and targeting related pathways could offer treatment options.
research Redefining hormone resistance in prostate cancer
The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
research HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond
Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.
research Inhibition of 17α-hydroxylase/C17,20 lyase reduces gating deficits consequent to dopaminergic activation
Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.
research Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19
Four drugs were found that could potentially treat COVID-19 by inhibiting the virus in lab tests.
research Editorial: Androgen-dependent diseases and their treatment
Continued research and awareness are needed to improve treatments for androgen-dependent diseases.
research Management of Advanced Prostate Cancer Undergoing Major Shift
New treatments are making advanced prostate cancer management more complex but also more hopeful.
research New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
research Hormone Blocking Anticancer Drugs
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
research FINASTERIDE AND PSA
research Bicalutamide
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
research 5-Alpha-Reductase Inhibitors and Combination Therapy
Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
research Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride
Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
research MP09-16 5-ALPHA REDUCTASE INHIBITORS FOR MALE LOWER URINARY TRACT SYMPTOMS: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
research Risk of age-related macular degeneration in men receiving 5α-reductase inhibitors: a population-based cohort study
Men taking dutasteride may have a higher risk of age-related macular degeneration.
research News & Notes
Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
research Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductase
Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
![Synthesis, Biological Evaluation, and Molecular Docking of 4-Amino-2H-benzo[h]chromen-2-one Analogs Containing the Piperazine Moiety](/images/research/2ecf4eed-7dbe-4f1a-83db-739625546cdd/small/31808.jpg)
research Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety
Analog 23 is a promising compound for prostate cancer treatment.
research Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.
Dutasteride effectively treats enlarged prostate with manageable side effects.
research [Two drugs have a better outcome. Finasteride plus alpha blocker improves urine flow].
research Synthesis and Study of Some 17a-aza-D-homo Steroids as 5α-Reductase Inhibitors
The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.